A jury for the US District Court of Delaware has confirmed the use of Magnolia’s patented Initial Specimen Diversion Device technology without permission from Kurin
Magnolia patented the Initial Specimen Diversion Technique and Initial Specimen Diversion Device for blood culture collection and contamination prevention. (Credit: Narupon Promvichai from Pixabay)
Magnolia Medical Technologies has won the patent-infringement lawsuit against Kurin regarding the illegal use of its Initial Specimen Diversion Device (ISDD) technology.
A jury for the U.S. District Court of Delaware delivered two unanimous decisions in Magnolia Medical Technologies’ favour.
Following a two-phased trial and brief deliberations, the jury confirmed that Kurin had utilised Magnolia Medical’s patented technology without authorisation.
Their judgement included considerable damages and validation of Magnolia Medical’s patent-protected technology.
Magnolia Medical CEO and co-founder Greg Bullington said: “Magnolia Medical Technologies is gratified by the jury’s unanimous verdicts in our favour this week, finding that Kurin, Inc. unlawfully used our innovative technology without permission.
“The verdicts reflect extensive evidence presented across two phases of trial, affirming the value of our innovative Steripath Initial Specimen Diversion Device technology and our leading position in the blood culture collection and contamination prevention market.”
Magnolia Medical has collaborated with several American hospitals and healthcare systems to solve the issue of blood culture contamination using Steripath.
The company is known for both technique and technology for blood culture collection for sepsis testing.
According to the firm, reducing blood culture contamination, which causes misdiagnosis of sepsis and unnecessary administration of broad-spectrum antibiotics, is one of the most effective methods to prevent multi-drug resistant organisms (MDROs).
The method also reduces the risk of antibiotic-related infections like Clostridioides difficile Infection (CDI), reducing the extended length of stay and healthcare costs.
Bullington added: “We take great pride in being an evidence-based company and having the only FDA 510(k)-cleared platform specifically indicated to reduce blood culture contamination and the only all-in-one device that meets the CDC’s new evidence-based guidelines for reducing blood culture contamination.”